Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways
暂无分享,去创建一个
[1] K. Kaye,et al. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. , 2022, JAMA.
[2] R. Longo,et al. Intravesical Gentamicin: An Option for Therapy and Prophylaxis against Recurrent UTIs and Resistant Bacteria in Neurogenic Bladder Patients on Intermittent Catheterization , 2022, Antibiotics.
[3] B. Somani,et al. Are Intravesical Aminoglycosides the New Gold Standard in the Management of Refractory Urinary Tract Infection: A Systematic Review of Literature , 2022, Journal of clinical medicine.
[4] P. Eckburg,et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. , 2022, The New England journal of medicine.
[5] R. Ohsfeldt,et al. A Cost-Effectiveness Analysis of Fosfomycin: A Single-Dose Antibiotic Therapy for Treatment of Uncomplicated Urinary Tract Infection , 2022, Health services insights.
[6] B. Nathanson,et al. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018 , 2022, Open forum infectious diseases.
[7] K. Chien,et al. Frailty increases the risk for developing urinary tract infection among 79,887 patients with diabetic mellitus and chronic kidney disease , 2021, BMC Geriatrics.
[8] R. Stafford,et al. Current Prescribing Practices and Guideline Concordance for the Treatment of Uncomplicated Urinary Tract Infections in Women. , 2021, American journal of obstetrics and gynecology.
[9] R. Walensky,et al. Addressing Antibiotic Overuse in the Outpatient Setting: Lessons From Behavioral Economics. , 2021, Mayo Clinic proceedings.
[10] R. Echols,et al. Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials , 2021, Open forum infectious diseases.
[11] R. Wunderink,et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. , 2020, The Lancet. Infectious diseases.
[12] Z. Tandoğdu,et al. Epidemiology, definition and treatment of complicated urinary tract infections , 2020, Nature Reviews Urology.
[13] D. MacFadden,et al. Improving Decision-making in Empiric Antibiotic Selection (IDEAS) for Gram-negative Bacteremia: A Prospective Clinical Implementation Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] N. Henderson,et al. The Natural History and Composition of Urinary Catheter Biofilms: Early Uropathogen Colonization with Intraluminal and Distal Predominance. , 2020, The Journal of urology.
[15] FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance , 2019, Case Medical Research.
[16] D. E. Smith,et al. MULTIPLEX PCR BASED URINARY TRACT INFECTION (UTI) ANALYSIS COMPARED TO TRADITIONAL URINE CULTURE IN IDENTIFYING SIGNIFICANT PATHOGENS IN SYMPTOMATIC PATIENTS. , 2019, Urology.
[17] T. File,et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] G. Sakoulas. FDA Approves Imipenem-Cilastatin/Relebactam (Recarbrio) for Complicated Intra-Abdominal or Urinary Tract Infections , 2019 .
[19] Anoop Kumar,et al. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. , 2019, Current drug safety.
[20] A. Flores-Mireles,et al. Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection. , 2019, Topics in spinal cord injury rehabilitation.
[21] J. Horcajada,et al. Oral and intravenous fosfomycin in complicated urinary tract infections , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[22] R. Chou,et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. , 2019, The Journal of urology.
[23] L. Rice,et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] L. Miller,et al. Once‐Daily Plazomicin for Complicated Urinary Tract Infections , 2019, The New England journal of medicine.
[25] L. Gesualdo,et al. Updates on urinary tract infections in kidney transplantation , 2019, Journal of Nephrology.
[26] M. Harber,et al. Impact of Urinary Tract Infections in Kidney Transplant Recipients: A 4-Year Single-Center Experience. , 2018, Transplantation proceedings.
[27] R. Echols,et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. , 2018, The Lancet. Infectious diseases.
[28] C. Tebé,et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections , 2018, Antimicrobial Resistance & Infection Control.
[29] S. Beatson,et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial , 2018, JAMA.
[30] B. Birch,et al. Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review , 2018, Current Urology Reports.
[31] B. Nathanson,et al. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections , 2018, Infection Control & Hospital Epidemiology.
[32] K. Kaye,et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial , 2018, JAMA.
[33] Michael Daniel,et al. An Implementation Guide to Reducing Overtreatment of Asymptomatic Bacteriuria , 2017, JAMA internal medicine.
[34] F. Bruyère,et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. , 2017, European urology.
[35] P. Thokala,et al. Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics , 2017, BJGP open.
[36] A. Cameron,et al. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[37] S. Kiertiburanakul,et al. A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli: A pilot study. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[38] Young Keun Kim,et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli , 2017, BMC Infectious Diseases.
[39] A. McDonnell,et al. Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study , 2017, BMJ Open.
[40] Z. Tandoğdu,et al. An update on classification and management of urosepsis , 2017, Current opinion in urology.
[41] Linnea A. Polgreen,et al. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011 , 2017, Open forum infectious diseases.
[42] Z. Tandoğdu,et al. Urinary Tract Infections in Immunocompromised Patients with Diabetes, Chronic Kidney Disease, and Kidney Transplant. , 2016, European urology focus.
[43] Jason G. Newland,et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. , 2016, JAMA.
[44] Elias Mossialos,et al. Targeting innovation in antibiotic drug discovery and development: The need for a One Health – One Europe – One World Framework [Internet] , 2016 .
[45] Z. Tandoğdu,et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013 , 2015, World Journal of Urology.
[46] Kayla R. Stover,et al. A Review of Antibiotic Use in Pregnancy , 2015, Pharmacotherapy.
[47] D. Paterson,et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology , 2015, Nature Reviews Urology.
[48] S. Hultgren,et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.
[49] A. Salonia,et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey. , 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[50] G. Montini,et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. , 2014, The New England journal of medicine.
[51] L. Rice,et al. MRSA and VRE Colonization in Solid Organ Transplantation: A Meta‐Analysis of Published Studies , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[52] N. Petersen,et al. Overtreatment of asymptomatic bacteriuria: identifying provider barriers to evidence-based care. , 2014, American journal of infection control.
[53] S. Saint,et al. Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update , 2014, Infection Control & Hospital Epidemiology.
[54] S. Calderwood,et al. Catheter-associated urinary tract infection in adults , 2014 .
[55] B. Zheng,et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study , 2013, BMJ Open.
[56] E. Leyten,et al. Diabetes and the Course of Febrile Urinary Tract Infection , 2013, Diabetes Care.
[57] Richard Smith,et al. The true cost of antimicrobial resistance , 2013, BMJ.
[58] Wendy R. Sanhai,et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. , 2013, The Lancet. Infectious diseases.
[59] K. Naber,et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. , 2011, International journal of antimicrobial agents.
[60] T. Berney,et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[61] U. Gafter,et al. Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: a systematic review and meta‐analysis , 2011, Transplant infectious disease : an official journal of the Transplantation Society.
[62] Richard Colgan,et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[63] H. Sipahi,et al. Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli-Related Complicated Lower Urinary Tract Infection , 2010, Journal of chemotherapy.
[64] Sanjay Saint,et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] Ethan M Balk,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.
[66] SUPPORTING TABLES,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[67] W. Hörl,et al. Urinary tract infection in renal transplant recipients , 2008, European journal of clinical investigation.
[68] C. Bonnal,et al. Bacteriuria in a geriatric hospital: impact of an antibiotic improvement program. , 2008, Journal of the American Medical Directors Association.
[69] C. Donskey,et al. Sustained reduction in inappropriate treatment of asymptomatic bacteriuria in a long-term care facility through an educational intervention. , 2008, American journal of infection control.
[70] S. Vimont,et al. Acute Pyelonephritis Represents a Risk Factor Impairing Long‐Term Kidney Graft Function , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[71] M. Haberal,et al. Urinary tract infections in renal transplant recipients. , 2003, Transplantation proceedings.
[72] O. Sipahi,et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. , 2007, International journal of antimicrobial agents.
[73] E. Hak,et al. Prediction of complicated urinary tract infections in patients with type 2 diabetes: a questionnaire study in primary care , 2007, European Journal of Epidemiology.
[74] L. Agodoa,et al. Late urinary tract infection after renal transplantation in the United States. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[75] S. Geerlings,et al. Pathogenesis of bacteriuria in women with diabetes mellitus. , 2002, International journal of antimicrobial agents.
[76] B. Dobkin,et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. , 2002, Archives of physical medicine and rehabilitation.
[77] M. Loeb,et al. Development of Minimum Criteria for the Initiation of Antibiotics in Residents of Long-Term–Care Facilities: Results of a Consensus Conference , 2001, Infection Control & Hospital Epidemiology.
[78] E. Hubbard,et al. Initiative , 2020, Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship.